Zacks Research Predicts Lower Earnings for Core Laboratories

Core Laboratories Inc. (NYSE:CLB - Free Report) - Analysts at Zacks Research lowered their Q3 2026 earnings per share (EPS) estimates for Core Laboratories in a note issued to investors on Tuesday, July 8th. Zacks Research analyst R. Department now expects that the oil and gas company will earn $0.16 per share for the quarter, down from their previous estimate of $0.19. The consensus estimate for Core Laboratories' current full-year earnings is $0.96 per share. Zacks Research also issued estimates for Core Laboratories' Q4 2026 earnings at $0.26 EPS, FY2026 earnings at $0.79 EPS and Q1 2027 earnings at $0.20 EPS.

Core Laboratories (NYSE:CLB - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The oil and gas company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Core Laboratories had a return on equity of 15.06% and a net margin of 5.41%. The company had revenue of $123.59 million for the quarter, compared to the consensus estimate of $125.09 million. During the same period last year, the firm posted $0.19 EPS. The company's revenue was down 4.7% compared to the same quarter last year.

Several other equities analysts have also issued reports on the company. Wall Street Zen lowered Core Laboratories from a "hold" rating to a "sell" rating in a research note on Friday, April 25th. Citigroup decreased their price objective on Core Laboratories from $16.00 to $13.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Finally, Stifel Nicolaus cut their target price on Core Laboratories from $19.00 to $15.00 and set a "hold" rating for the company in a research note on Tuesday, April 15th. Two equities research analysts have rated the stock with a sell rating and three have assigned a hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $15.00.

Core Laboratories Stock Performance

Shares of CLB traded down $0.05 during trading hours on Thursday, reaching $12.89. 247,183 shares of the company traded hands, compared to its average volume of 413,272. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.64 and a current ratio of 2.21. The stock's fifty day moving average is $11.82 and its 200 day moving average is $14.25. Core Laboratories has a 1-year low of $10.14 and a 1-year high of $25.13. The stock has a market cap of $604.28 million, a P/E ratio of 21.85, a price-to-earnings-growth ratio of 3.96 and a beta of 1.41.

Core Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, May 27th. Shareholders of record on Monday, May 5th were paid a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date of this dividend was Monday, May 5th. Core Laboratories's dividend payout ratio is 6.78%.

Institutional Investors Weigh In On Core Laboratories

A number of institutional investors have recently added to or reduced their stakes in CLB. Millennium Management LLC raised its holdings in shares of Core Laboratories by 429.0% in the 4th quarter. Millennium Management LLC now owns 65,616 shares of the oil and gas company's stock worth $1,136,000 after buying an additional 53,213 shares in the last quarter. Franklin Resources Inc. bought a new stake in Core Laboratories in the fourth quarter valued at $464,000. Amundi raised its stake in Core Laboratories by 194.8% during the fourth quarter. Amundi now owns 32,968 shares of the oil and gas company's stock worth $600,000 after acquiring an additional 21,783 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in shares of Core Laboratories by 19.8% during the first quarter. Oppenheimer Asset Management Inc. now owns 69,184 shares of the oil and gas company's stock valued at $1,037,000 after acquiring an additional 11,438 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Core Laboratories by 15.6% during the fourth quarter. Northern Trust Corp now owns 577,752 shares of the oil and gas company's stock valued at $10,001,000 after acquiring an additional 78,173 shares during the period. 97.81% of the stock is owned by institutional investors and hedge funds.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.